Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis

Puntos clave

• Better outcomes are observed with amivantamab and chemotherapy for EGFR exon 20 mutated lung cancer.
• Patients treated with amivantamab plus chemotherapy showed a 50% increase in progression-free survival.
• Analysis of data from Asia indicates a significant benefit for advanced non-small cell lung cancer patients.
• Findings highlight the need for targeted therapies in enhancing treatment strategies.